Literature DB >> 17059853

Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.

Odilia Popanda1, Lutz Edler, Peter Waas, Torsten Schattenberg, Dorota Butkiewicz, Thomas Muley, Hendrik Dienemann, Angela Risch, Helmut Bartsch, Peter Schmezer.   

Abstract

Alterations in cell cycle regulation and apoptosis leading to malignant transformation could be caused by common genetic variants in tumor suppressor genes. The effects of the TP53 polymorphism Arg72Pro on lung cancer risk have been investigated in numerous studies with, however, conflicting results. In many studies, important risk modifiers such as smoking or tumor histology were not taken into account. We therefore investigated the combined effects of polymorphisms in TP53 (Arg72Pro) and p21/CDKN1A (Ser31Arg) and smoking on lung cancer risk. Our case-control study consisted of 405 patients with lung cancer, mainly squamous-cell carcinoma (185) and adenocarcinoma (177) and 404 unmatched tumor-free hospital controls. Multivariate regression analysis showed a moderate but statistically significant risk of lung cancer overall and especially of squamous-cell carcinoma (OR, 1.65; CI, 1.10-2.47) for TP53 72Pro allele carriers. The risk was markedly increased in heavy smokers (>20 pack-years) with squamous-cell carcinoma (OR, 2.80 in patients homozygous for 72Pro; CI, 1.19-6.58), but not in light smokers (<or=20 pack-years). The results for the p21 Ser31Arg polymorphism suggested that 31Ser is a moderate-risk allele for squamous-cell carcinoma. Analysis of the combined effects of the two polymorphisms revealed a higher OR for TP53 72Pro carriers homozygous for p21 31Ser than for 72Pro carriers in general; this effect being most pronounced in heavy smokers with squamous-cell carcinoma (OR, 3.84; CI, 1.46-10.1). Our data indicate that the TP53 Arg72Pro polymorphism increases the risk for squamous-cell carcinoma mainly in heavy smokers. The observed interaction with smoking is biologically plausible as, for the 72Pro p53 variant, decreased apoptosis and extended G1 cell cycle arrest is reported after carcinogen exposure. Nevertheless, confirmation by further molecular and epidemiological studies is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059853     DOI: 10.1016/j.lungcan.2006.09.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  20 in total

1.  Comprehensive assessment of P21 polymorphisms and lung cancer risk.

Authors:  Yi Young Choi; Hyo-Kyung Kang; Jin Eun Choi; Jin Sung Jang; Eun Jin Kim; Sung Ick Cha; Won Kee Lee; Sin Kam; Chang Ho Kim; Sung Beom Han; Tae Hoon Jung; Jae Yong Park
Journal:  J Hum Genet       Date:  2007-11-28       Impact factor: 3.172

2.  Correlating observed odds ratios from lung cancer case-control studies to SNP functional scores predicted by bioinformatic tools.

Authors:  Yong Zhu; Aaron Hoffman; Xifeng Wu; Heping Zhang; Yawei Zhang; Derek Leaderer; Tongzhang Zheng
Journal:  Mutat Res       Date:  2007-11-26       Impact factor: 2.433

3.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

4.  Association study of TP53 polymorphisms with lung cancer in a Korean population.

Authors:  Hae-Yun Jung; Young Mi Whang; Jae Sook Sung; Hyoung Doo Shin; Byung Lae Park; Jun Suk Kim; Sang Won Shin; Hee Yun Seo; Jae Hong Seo; Yeul Hong Kim
Journal:  J Hum Genet       Date:  2008-03-25       Impact factor: 3.172

5.  Polymorphisms in DNA repair genes and breast cancer risk in Russian population: a case-control study.

Authors:  Alexandra S Shadrina; Natalia A Ermolenko; Uljana A Boyarskikh; Tatiana V Sinkina; Alexandr F Lazarev; Valentina D Petrova; Maxim L Filipenko
Journal:  Clin Exp Med       Date:  2014-12-24       Impact factor: 3.984

Review 6.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

7.  Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.

Authors:  Ankita Kumari; Charu Bahl; Navneet Singh; Digambar Behera; Siddharth Sharma
Journal:  Mol Biol Rep       Date:  2016-09-10       Impact factor: 2.316

8.  P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects.

Authors:  Chao Zhou; Hao Chen; An Wang
Journal:  Tumour Biol       Date:  2013-05-30

9.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies.

Authors:  Shengming Dai; Chen Mao; Lijun Jiang; Guisheng Wang; Hongge Cheng
Journal:  Hum Genet       Date:  2009-04-09       Impact factor: 4.132

10.  Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer.

Authors:  Jinyun Chen; Ann M Killary; Subrata Sen; Christopher I Amos; Douglas B Evans; James L Abbruzzese; Marsha L Frazier
Journal:  Cancer Lett       Date:  2008-08-09       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.